PBAC's latest decision on Sunitinib malate: Deferred (2012). Considered for initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (or carcinoma) (pancreatic NET) in a patient who is symptomatic (despite somatostatin analogues) or has documented disease progression.
PBAC outcome
Deferred
Authority Required
ICER (AUD/QALY)
$75k/QALY
$45k/QALY–$75k/QALY · across 7 submissions
Submissions
8
first 2007
Submissions
8
2007 → 2012
Eligible population
patients with metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (or carcinoma) (pancreatic NET) who are symptomatic (despite somatostatin analogues) or have documented disease progression
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
PFS, OS
Key trials
A618-1111
Comparator
best supportive care (placebo)
Economic model
CUA
ICER basis
Range aggregates 7 submissions (2007–2012) — not a single base case.
Submission history
Mar 2007: Deferred · Authority Required — ICER $105k/QALY
Mar 2007: Deferred
Mar 2008: Not recommended · Authority Required — ICER $200k/QALY
Mar 2008: Not recommended · Authority Required — ICER $105k/QALY